Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 23,263 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $22.76, for a total value of $529,465.88. Following the completion of the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at $4,260,876.84. The trade was a 11.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Omada Health Stock Performance
Shares of NASDAQ OMDA traded down $0.02 during mid-day trading on Wednesday, reaching $22.98. The company’s stock had a trading volume of 1,251,953 shares, compared to its average volume of 1,096,319. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92. The stock has a fifty day moving average of $17.83 and a two-hundred day moving average of $15.27.
Omada Health (NASDAQ:OMDA – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%.The company had revenue of $78.05 million for the quarter. As a group, equities research analysts predict that Omada Health, Inc. will post -0.01 EPS for the current fiscal year.
Hedge Funds Weigh In On Omada Health
Analysts Set New Price Targets
OMDA has been the subject of a number of research reports. Weiss Ratings upgraded shares of Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. Barclays lifted their price target on shares of Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Citigroup reissued an “outperform” rating on shares of Omada Health in a report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and set a $30.00 price objective on shares of Omada Health in a research report on Monday, June 22nd. Finally, Citizens Jmp lifted their target price on Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Omada Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.
View Our Latest Stock Analysis on Omada Health
Omada Health Company Profile
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Read More
- Five stocks we like better than Omada Health
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
